HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma

Thomas P Miller, S. M. Lippman, Catherine S Perry, D. J. Slymen, T. M. Grogan

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

The clinical utility for establishing the immune phenotype in patients with non-Hodgkin's lymphoma is controversial. To help resolve this dilemma, we studied 104 consecutive patients with diffuse large cell lymphoma, the most common subtype of potentially curable non-Hodgkin's lymphomas. The presence or absence of the human class II histocompatibility antigen was determined using the monoclonal antibody anti-HLA-DR (Ia), and the results correlated with pretreatment clinical features and survival. We found that eight HLA-DR negative patients had similar pretreatment clinical characteristics compared with 96 HLA-DR positive patients, but HLA-DR negative patients had a significantly shorter survival duration compared with HLA-DR positive patients (P = 0.003 log-rank). The median survival of the HLA-DR negative patients was 0.5 years compared to 2.8 yr for the HLA-DR positive patients. No HLA-DR negative patient survived beyond 1.5 yr. A multivariate analysis, adjusting for prognostic factors of known clinical significance, confirmed the importance of HLA-DR as a prognostic factor (P = 0.016). We conclude that determining the presence of HLA-DR is a relatively simple pretreatment study that identifies a small but important group of patients who are not curable using currently available combination chemotherapy.

Original languageEnglish (US)
Pages (from-to)370-372
Number of pages3
JournalJournal of Clinical Investigation
Volume82
Issue number1
StatePublished - 1988

Fingerprint

Lymphoma, Large B-Cell, Diffuse
HLA-DR Antigens
Phenotype
Non-Hodgkin's Lymphoma
HLA-D Antigens
Histocompatibility
Survival
Combination Drug Therapy
Multivariate Analysis
Monoclonal Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. / Miller, Thomas P; Lippman, S. M.; Perry, Catherine S; Slymen, D. J.; Grogan, T. M.

In: Journal of Clinical Investigation, Vol. 82, No. 1, 1988, p. 370-372.

Research output: Contribution to journalArticle

@article{e6017d1bd5794da3910002e30f2fa8d4,
title = "HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma",
abstract = "The clinical utility for establishing the immune phenotype in patients with non-Hodgkin's lymphoma is controversial. To help resolve this dilemma, we studied 104 consecutive patients with diffuse large cell lymphoma, the most common subtype of potentially curable non-Hodgkin's lymphomas. The presence or absence of the human class II histocompatibility antigen was determined using the monoclonal antibody anti-HLA-DR (Ia), and the results correlated with pretreatment clinical features and survival. We found that eight HLA-DR negative patients had similar pretreatment clinical characteristics compared with 96 HLA-DR positive patients, but HLA-DR negative patients had a significantly shorter survival duration compared with HLA-DR positive patients (P = 0.003 log-rank). The median survival of the HLA-DR negative patients was 0.5 years compared to 2.8 yr for the HLA-DR positive patients. No HLA-DR negative patient survived beyond 1.5 yr. A multivariate analysis, adjusting for prognostic factors of known clinical significance, confirmed the importance of HLA-DR as a prognostic factor (P = 0.016). We conclude that determining the presence of HLA-DR is a relatively simple pretreatment study that identifies a small but important group of patients who are not curable using currently available combination chemotherapy.",
author = "Miller, {Thomas P} and Lippman, {S. M.} and Perry, {Catherine S} and Slymen, {D. J.} and Grogan, {T. M.}",
year = "1988",
language = "English (US)",
volume = "82",
pages = "370--372",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma

AU - Miller, Thomas P

AU - Lippman, S. M.

AU - Perry, Catherine S

AU - Slymen, D. J.

AU - Grogan, T. M.

PY - 1988

Y1 - 1988

N2 - The clinical utility for establishing the immune phenotype in patients with non-Hodgkin's lymphoma is controversial. To help resolve this dilemma, we studied 104 consecutive patients with diffuse large cell lymphoma, the most common subtype of potentially curable non-Hodgkin's lymphomas. The presence or absence of the human class II histocompatibility antigen was determined using the monoclonal antibody anti-HLA-DR (Ia), and the results correlated with pretreatment clinical features and survival. We found that eight HLA-DR negative patients had similar pretreatment clinical characteristics compared with 96 HLA-DR positive patients, but HLA-DR negative patients had a significantly shorter survival duration compared with HLA-DR positive patients (P = 0.003 log-rank). The median survival of the HLA-DR negative patients was 0.5 years compared to 2.8 yr for the HLA-DR positive patients. No HLA-DR negative patient survived beyond 1.5 yr. A multivariate analysis, adjusting for prognostic factors of known clinical significance, confirmed the importance of HLA-DR as a prognostic factor (P = 0.016). We conclude that determining the presence of HLA-DR is a relatively simple pretreatment study that identifies a small but important group of patients who are not curable using currently available combination chemotherapy.

AB - The clinical utility for establishing the immune phenotype in patients with non-Hodgkin's lymphoma is controversial. To help resolve this dilemma, we studied 104 consecutive patients with diffuse large cell lymphoma, the most common subtype of potentially curable non-Hodgkin's lymphomas. The presence or absence of the human class II histocompatibility antigen was determined using the monoclonal antibody anti-HLA-DR (Ia), and the results correlated with pretreatment clinical features and survival. We found that eight HLA-DR negative patients had similar pretreatment clinical characteristics compared with 96 HLA-DR positive patients, but HLA-DR negative patients had a significantly shorter survival duration compared with HLA-DR positive patients (P = 0.003 log-rank). The median survival of the HLA-DR negative patients was 0.5 years compared to 2.8 yr for the HLA-DR positive patients. No HLA-DR negative patient survived beyond 1.5 yr. A multivariate analysis, adjusting for prognostic factors of known clinical significance, confirmed the importance of HLA-DR as a prognostic factor (P = 0.016). We conclude that determining the presence of HLA-DR is a relatively simple pretreatment study that identifies a small but important group of patients who are not curable using currently available combination chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0023816791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023816791&partnerID=8YFLogxK

M3 - Article

VL - 82

SP - 370

EP - 372

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 1

ER -